Successful use of fondaparinux in a child with heparin-induced thrombocytopenia

• DOI: 10.1097/mbc.0b013e328358afc9
• Publication Date: 2012-09-07T07:35:16Z
• Authors: Huseyin Tokgoz; Umran Caliskan; Muzaffer Demir
• Keywords: Fondaparinux; Discontinuation; Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is a well described side effect of heparin therapy. A 12-year-old boy developed deep-vein thrombosis. Risk factors for initial thrombosis are antiphospholipid syndrome and heterozygous mutation prothrombin G20210A. Anticoagulant therapy with warfarin 12 months was effective, but discontinuation after resulted in recurrence Unfractionated (UFH) initiated during the acute period, heparin-induced developed. Transition from UFH to fondaparinux successful anticoagulation period platelet recovery. We report case HIT developing background prothrombotic genetic risk syndrome. This study highlights several difficulties pediatric cases.